CORRESP 1 filename1.htm Blueprint
Q BioMed Inc.
c/o Ortoli Rosenstadt LLP
501 Madison Avenue – 14th Floor
New York, NY 10022
Telephone: 212-588-0022
Fax: 212-826-9307
January 12, 2018
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Q BioMed Inc. (the “Company)
Registration Statement on Form S-1
File No. 333-222008 (the “Registration Statement”)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above, as most recently amended, be accelerated so that it will be declared effective at 4:00 pm on Friday, January 12, 2018, or as soon thereafter as is practicable.
The Company acknowledges that:
should the Commission or the staff, acting pursuant to delegated authority, declares the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Q BioMed Inc.
/s/ Denis Corin
Denis Corin
Chairman & Chief Executive Officer